Literature DB >> 8960145

A clinical study of 130 patients with biliary tract cancers and periampullary tumors.

W C Su1, K K Chan, X Z Lin, P W Lin, N H Chow, J S Shin, C Y Chen, C J Tsao.   

Abstract

A retrospective review of 130 patients with peripheral-type cholangiocarcinomas (PTCC), hilar-type cholangiocarcinomas (HTCC), extrahepatic cholangiocarcinomas (EHCC), gallbladder cancers (GBCA), and periampullary cancers (PACA), seen at National Cheng Kung University Hospital and Tainan Municipal Hospital from June 1987 to July 1993 was performed. There were 47 (36%) HTCC, 32 (25%) PACA, 24 (19%) PTCC, 17 (13%) GBCA, and 10 (8%) EHCC patients. The distribution is completely different from that reported in western countries. These cancers mainly occur in elderly patients. HTCC and GBCA were predominantly noted in female patients. Biliary cancers in Taiwan were not related to liver fluke infestation, inflammatory bowel disease or hepatitis B virus infection. However, a close association with biliary lithiasis was found. The incidence of gallstones was 67, 39, 20, 29 and 19% for PTCC, HTCC, EHCC, GBCA and PACA, respectively. The most common presentation for PTCC and GBCA was abdominal pain, or jaundice for HTCC, EHCC and PACA. These symptoms correlate well with the location of the tumors. Among serum tumor markers, the elevation of CA19-9 was most frequent, occurring in 86% of the patients while CA125 and CEA occurred in 47% and 30% of the patients, respectively. During the course of disease, infection developed in 61% of the patients and was the main cause of death in 25%. Biliary tract infection and sepsis were the two leading manifestations and occurred in 49% and 32% of the patients, respectively. Overall survival was poor except in patients whose tumor could be completely resected.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960145     DOI: 10.1159/000227625

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

1.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Authors:  Xing-Lei Qin; Zhuo-Ren Wang; Jing-Sen Shi; Min Lu; Lin Wang; Quan-Ru He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders.

Authors:  W C Su; S C Shiesh; H S Liu; C Y Chen; N H Chow; X Z Lin
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

3.  Epidemiology of primary and secondary liver cancers.

Authors:  Ashwin Ananthakrishnan; Veena Gogineni; Kia Saeian
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

4.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

5.  Mesothelin as a potential therapeutic target in human cholangiocarcinoma.

Authors:  Liping Yu; Mingqian Feng; Heungnam Kim; Yen Phung; David E Kleiner; Gregory J Gores; Min Qian; Xin Wei Wang; Mitchell Ho
Journal:  J Cancer       Date:  2010-10-01       Impact factor: 4.207

6.  Cholecystectomy, liver resection, and pylorus-preserving pancreaticoduodenectomy for gallbladder cancer: report of five cases.

Authors:  John R Doty; John L Cameron; Charles J Yeo; Kurtis Campbell; JoAnn Coleman; Ralph H Hruban
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

7.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.

Authors:  T Uenishi; S Kubo; K Hirohashi; H Tanaka; T Shuto; T Yamamoto; S Nishiguchi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.